DENTALI, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 25.199
EU - Europa 13.671
AS - Asia 3.594
SA - Sud America 56
Continente sconosciuto - Info sul continente non disponibili 33
OC - Oceania 11
AF - Africa 8
Totale 42.572
Nazione #
US - Stati Uniti d'America 25.152
IT - Italia 6.971
UA - Ucraina 2.279
TR - Turchia 1.610
SE - Svezia 1.186
IE - Irlanda 798
DE - Germania 792
VN - Vietnam 732
CN - Cina 702
FI - Finlandia 523
GB - Regno Unito 430
SG - Singapore 420
RU - Federazione Russa 335
FR - Francia 195
IN - India 45
CA - Canada 41
BR - Brasile 36
JP - Giappone 30
EU - Europa 29
BE - Belgio 27
NL - Olanda 27
CZ - Repubblica Ceca 17
CL - Cile 11
AU - Australia 10
ES - Italia 9
LT - Lituania 9
CH - Svizzera 8
GR - Grecia 8
PT - Portogallo 8
RO - Romania 8
IR - Iran 7
PL - Polonia 7
AT - Austria 6
HK - Hong Kong 5
AL - Albania 4
AR - Argentina 4
HU - Ungheria 4
ID - Indonesia 4
PH - Filippine 4
RS - Serbia 4
TH - Thailandia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AE - Emirati Arabi Uniti 3
EG - Egitto 3
IL - Israele 3
KR - Corea 3
MK - Macedonia 3
MX - Messico 3
MY - Malesia 3
NO - Norvegia 3
PK - Pakistan 3
BD - Bangladesh 2
BO - Bolivia 2
DK - Danimarca 2
HN - Honduras 2
KW - Kuwait 2
LI - Liechtenstein 2
LK - Sri Lanka 2
PE - Perù 2
SI - Slovenia 2
TW - Taiwan 2
A1 - Anonimo 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
CR - Costa Rica 1
DZ - Algeria 1
EC - Ecuador 1
IQ - Iraq 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MA - Marocco 1
MD - Moldavia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 42.572
Città #
Milan 5.038
Fairfield 4.108
Woodbridge 2.671
Ashburn 2.028
Houston 1.922
Jacksonville 1.808
Seattle 1.604
Wilmington 1.492
Chandler 1.387
Cambridge 1.384
Ann Arbor 1.312
Izmir 813
Dublin 793
Princeton 787
Dearborn 591
Nyköping 539
Boardman 498
Singapore 390
Dong Ket 367
Rome 323
San Diego 243
San Mateo 159
Ogden 152
Beijing 129
Como 127
Chicago 120
Washington 102
London 101
Santa Clara 82
New York 74
Düsseldorf 70
Helsinki 69
Hefei 63
Redmond 62
Los Angeles 61
Nanjing 59
Norwalk 53
Kunming 51
Verona 50
Kocaeli 39
Munich 38
Paris 38
Dallas 31
Frankfurt am Main 30
Jinan 30
Kilburn 30
Toronto 29
Guangzhou 24
Nanchang 24
Tokyo 24
Brussels 22
Besana In Brianza 20
Falls Church 19
Ponte Lambro 19
Redwood City 19
Prescot 18
Fuzhou 17
Chiswick 16
Varese 16
Brno 15
Shenyang 15
Acton 14
Berlin 14
Indiana 14
Philadelphia 13
Zhengzhou 13
Bergamo 12
Hounslow 12
Changsha 11
San Francisco 11
São Paulo 11
Wandsworth 11
Wuhan 11
Busto Arsizio 10
Genoa 10
Hebei 10
New Bedfont 10
Pune 10
Southwark 10
Xian 10
Islington 9
Legnano 9
Parma 8
Phoenix 8
Ralingen 8
Suresnes 8
Brescia 7
Chongqing 7
Hangzhou 7
Magnago 7
Ningbo 7
Tianjin 7
Torino 7
Abbiategrasso 6
Detroit 6
Florence 6
Lappeenranta 6
Saint Louis 6
Shanghai 6
Amsterdam 5
Totale 32.572
Nome #
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis 238
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery 227
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature 227
Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both 223
Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal 220
Risk of recurrence of unusual site venous thromboembolism 214
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment 205
A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study 204
Impact of neutrophils to lymphocytes ratio on major clinical outcomes in patients with acute coronary syndromes: A systematic review and meta-analysis of the literature 199
PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis 196
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry 194
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome 194
Optimal treatment duration of venous thrombosis 191
incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio. 190
Pulmonary Embolism Severity Index Accurately Predicts Long-Term Mortality Rate In Patients Hospitalized For Acute Pulmonary Embolism 187
Patient selection for thromboprophylaxis in medical inpatients 186
Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis. 186
Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study 186
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. 180
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable? 180
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice 180
Venous ischemic syndromes 180
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature 179
Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis 178
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data 177
Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis 175
Warfarin interactions with antibiotics in the ambulatory care setting 174
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation 172
Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens 171
Duration of anticoagulation after venous thromboembolism in real world clinical practice 170
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism 170
Venous and arterial thrombosis in patients with HIV infection 169
Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis 169
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy 169
Seasonal and monthly variation in occurrence of hypertensive urgency 168
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis 165
Factors associated with anticoagulation prescription in elderly patients with atrial fibrillation 165
ABO blood group and vascular disease: an update 164
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature 164
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study 163
Management of primary care patients with suspected deep vein thrombosis: use of a therapeutic dose of low-molecular-weight heparin to avoid urgent ultrasonographic evaluation. 163
Statins and secondary prevention of ischemic and hemorrhagic stroke 162
Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature 162
Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding 161
Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians 161
Predictors of residual venous obstruction after deep vein thrombosis of the lower limbs: a prospective cohort study 160
Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment 158
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage 158
Is diabetes a hypercoagulable state? A critical appraisal 158
Low-molecular -weight heparin in pregnancies after ART -A retrospective study- 158
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree? 157
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: A multicenter retrospective cohort study 157
sRAGE and early signs of cardiac target organ damage in mild hypertensives 157
Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension. 156
Intracranial bleeding risk after minor traumatic brain injury in patients on antithrombotic drugs 156
The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature 155
Prevention of in-hospital VTE: why can't we do better? 154
In vitro effects of Apixaban on 5 different cancer cell lines 154
The role of thrombolytic therapy in pulmonary embolism 153
Low ankle-brachial index predicts an adverse 1-year outcome after acute coronary and cerebrovascular events 153
How I treat splanchnic vein thrombosis 152
Statins for acute ischemic stroke 152
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature: a reply to a rebuttal 151
Antithrombotic and fibrinolytic drugs for retinal vein occlusion: a systematic review and a call for action. 150
The initial phase of oral anticoagulation with warfarin in outpatients with deep venous thrombosis. 149
Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE Study 149
Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism: Comment 149
In-hospital mortality due to pulmonary embolism in patients with Alzheimer disease: A sex effect? 149
The effect of thyroid autoantibodies on warfarin stability 149
Italian intersociety consensus on DOAC use in internal medicine 147
Clinical utility of antithrombotic prophylaxis in ART procedures: an Italian experience 146
Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes 146
Association between the metabolic syndrome, its individual components, and unprovoked venous thromboembolism: Results of a patient-level meta-analysis 146
Direct oral anticoagulants for superficial-vein thrombosis 146
The prevention and treatment of venous thromboembolism in pregnancy 146
Atypical case of Acute Coronary Syndrome due to Coronary-Pulmonary Steal Syndrome secondary to Pulmonary Embolism. 145
Management of hypertension in overweight and obese patients: a practical guide for clinicians. 145
Clinical Pregnancies and Live Births in women approaching ART: a follow-up analysis of 157 women after thrombophilia screening 145
Neutrophil-to-lymphocyte ratio: A new prognostic factor even in patients with heart failure 144
A prospective validation of the Bova score in normotensive patients with acute pulmonary embolism 144
Inferior vena cava filter in patients with venous thromboembolism and major bleeding events: building the evidence 144
JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. 144
Risk of Thromboembolism, Recurrent Hemorrhage, and Death after Warfarin Therapy Interruption for Gastrointestinal Tract Bleeding 144
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases 143
Antithrombin levels and the risk of a first episode of venous thromboembolism: a case-control study 143
American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy 143
Metabolic syndrome and hyperhomocysteinemia in patients with deep vein thrombosis: a case-control study 142
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. 142
Nonadherence with INR monitoring and anticoagulant complications 142
Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se. 140
Natural anticoagulants deficiency and the risk of venous thromboembolism: A meta-analysis of observational studies 140
Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increased risk of venous thromboembolic events. 139
Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study. 139
Statins, fibrates, and venous thromboembolism: a meta-analysis. 139
Short-term prognosis of intracranial haemorrhage in patients on oral anticoagulant or antiplatelet drugs 138
Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism: A multicentre retrospective cohort study 138
Prognostic role of neutrophils to lymphocytes ratio in patients with acute pulmonary embolism: a systematic review and meta-analysis of the literature 138
Evaluation of right ventricular function in patients with a previous episode of pulmonary embolism using tissue Doppler imaging. 137
5 flourouracil-induced apical ballooning syndrome: a case report. 137
The role of the metabolic syndrome in patients with provoked venous thromboembolic events 137
Totale 16.361
Categoria #
all - tutte 187.694
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 187.694


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.196 0 0 0 0 0 965 1.231 1.043 721 571 169 496
2020/20217.056 145 653 766 695 409 732 291 619 838 458 574 876
2021/20224.033 403 544 187 104 219 172 325 215 229 726 411 498
2022/20234.395 480 206 318 379 303 956 14 577 652 247 141 122
2023/20248.254 1.250 1.289 1.290 1.568 1.646 576 66 120 242 96 43 68
2024/20252.051 46 52 1.126 179 237 411 0 0 0 0 0 0
Totale 43.094